Overall Score

Revenue Model

Primarily a recurring revenue medtech model with revenue per share of 5.25 and gross margin of 66.1%.

No dividend, so cash generation must come from operations rather than capital returns.

Profitability

TTM margins remain negative at -13.5% net margin and -5.6% operating margin despite 66.1% gross margin.

Returns remain weak with ROIC at -7.2% and ROE at -8.2%.

Cash Generation

Operating cash flow is positive at 0.24 OCF ratio, but free cash flow conversion is very weak with FCF yield at 0.3% and FCF per share of 0.03.

High capex intensity and working-capital needs keep cash conversion constrained, with a cash conversion cycle of 225 days.

Balance Sheet

Liquidity is adequate with a current ratio of 1.89 and quick ratio of 1.07.

Leverage remains elevated, with debt-to-assets at 76.4% and net debt to EBITDA at 36.1x.

Operating Efficiency

Asset turnover is solid at 1.03x and fixed asset turnover is 4.84x.

Inventory efficiency is still a drag, with 257.8 days of inventory outstanding and a 307.1-day operating cycle.